Galapagos NV (VIE:GLPG)

Market Cap	1.69B +6.6%
Revenue (ttm)	1.11B +303.5%
Net Income	320.88M +333.1%
EPS	4.87 +333.7%
Shares Out	n/a
PE Ratio	5.26
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	104
Open	25.54
Previous Close	25.80
Day's Range	25.40 - 25.64
52-Week Range	20.72 - 32.20
Beta	n/a
RSI	35.00
Earnings Date	Mar 26, 2026

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 704
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: GLPG

Financial Performance

In 2025, Galapagos NV's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.